HEMERA-1 氧代羧基血红蛋白用于急性中风血管扩张:前瞻性随机 1 期临床试验

Italo Linfante, W. Clark, D. Houssen, Ricardo A. Hanel, Rwoof A Reshi, G. Dabus, Ronald Jubin, Mona P. Roshan, Star Belnap, Thanh N. Nguyen, J. Grotta, R. Wicks, M. Cipolla, David S. Liebeskind, Raul G. Nogueira
{"title":"HEMERA-1 氧代羧基血红蛋白用于急性中风血管扩张:前瞻性随机 1 期临床试验","authors":"Italo Linfante, W. Clark, D. Houssen, Ricardo A. Hanel, Rwoof A Reshi, G. Dabus, Ronald Jubin, Mona P. Roshan, Star Belnap, Thanh N. Nguyen, J. Grotta, R. Wicks, M. Cipolla, David S. Liebeskind, Raul G. Nogueira","doi":"10.1161/svin.123.001246","DOIUrl":null,"url":null,"abstract":"\n \n PP‐007 is a polyethylene glycol (PEG)ylated bovine carboxyhemoglobin gas transfer molecule with pleotropic cytoprotective effects, vasodilatation, plasma expansion, and optimization of oxygen delivery. Rodent middle cerebral artery occlusion models have demonstrated that PP‐007 increases blood flow in the collateral circulation and reduces final infarct volumes, supporting a potential role as neuroprotective agent in acute ischemic stroke. We aim to evaluate the safety and feasibility of PP‐007 as an adjunctive treatment to mechanical thrombectomy (MT) in patients with stroke secondary to large vessel occlusion.\n \n \n \n HEMERA‐1 (CarboxyHEMoglobin OxygEn delivery for Revascularization in Acute Stroke) was a multicenter, prospective, randomized, controlled phase 1 clinical trial. Anterior circulation large vessel occlusion patients were assigned in a 3:1 ratio to receive either PP‐007 (320 mg/kg: 30 min bolus followed by 2‐h infusion) plus MT or MT alone within 24 hours after symptom onset. Comprehensive safety evaluation was performed by independent Data Monitoring Safety Board and Imaging Core Lab.\n \n \n \n From October 1, 2021 to June 30, 2022, a total of 17 patients were recruited. Age, baseline National Institutes of Health Stroke Scale score, and Alberta Stroke Program Early CT Score were 74.8±12.7 years, 17.3±4.2, and 7.9±1.8, respectively. Twelve patients were randomized to PP‐007 plus MT, 1 was randomized but not treated, 4 patients were randomized to MT alone. Recanalization of the occluded vessel was achieved in all patients. A transient systolic blood pressure increase (20–40 mm Hg) during the bolus was observed in all PP‐007 patients without any clinical consequences. There were no other safety concerns.\n \n \n \n No significant safety concerns were identified for the adjunctive use of PP‐007 in patients undergoing MT. (The study was funded by Prolong Pharmaceuticals.\n \n \n \n \n URL:\n https://www.clinicaltrials.gov\n ; Unique identifier: NCT04677777.\n \n","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":"27 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HEMERA‐1 CarboxyHEMoglobin OxygEn Delivery for Evascularization in Acute Stroke: A Prospective, Randomized Phase 1 Clinical Trial\",\"authors\":\"Italo Linfante, W. Clark, D. Houssen, Ricardo A. Hanel, Rwoof A Reshi, G. Dabus, Ronald Jubin, Mona P. Roshan, Star Belnap, Thanh N. Nguyen, J. Grotta, R. Wicks, M. Cipolla, David S. Liebeskind, Raul G. Nogueira\",\"doi\":\"10.1161/svin.123.001246\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n PP‐007 is a polyethylene glycol (PEG)ylated bovine carboxyhemoglobin gas transfer molecule with pleotropic cytoprotective effects, vasodilatation, plasma expansion, and optimization of oxygen delivery. Rodent middle cerebral artery occlusion models have demonstrated that PP‐007 increases blood flow in the collateral circulation and reduces final infarct volumes, supporting a potential role as neuroprotective agent in acute ischemic stroke. We aim to evaluate the safety and feasibility of PP‐007 as an adjunctive treatment to mechanical thrombectomy (MT) in patients with stroke secondary to large vessel occlusion.\\n \\n \\n \\n HEMERA‐1 (CarboxyHEMoglobin OxygEn delivery for Revascularization in Acute Stroke) was a multicenter, prospective, randomized, controlled phase 1 clinical trial. Anterior circulation large vessel occlusion patients were assigned in a 3:1 ratio to receive either PP‐007 (320 mg/kg: 30 min bolus followed by 2‐h infusion) plus MT or MT alone within 24 hours after symptom onset. Comprehensive safety evaluation was performed by independent Data Monitoring Safety Board and Imaging Core Lab.\\n \\n \\n \\n From October 1, 2021 to June 30, 2022, a total of 17 patients were recruited. Age, baseline National Institutes of Health Stroke Scale score, and Alberta Stroke Program Early CT Score were 74.8±12.7 years, 17.3±4.2, and 7.9±1.8, respectively. Twelve patients were randomized to PP‐007 plus MT, 1 was randomized but not treated, 4 patients were randomized to MT alone. Recanalization of the occluded vessel was achieved in all patients. A transient systolic blood pressure increase (20–40 mm Hg) during the bolus was observed in all PP‐007 patients without any clinical consequences. There were no other safety concerns.\\n \\n \\n \\n No significant safety concerns were identified for the adjunctive use of PP‐007 in patients undergoing MT. (The study was funded by Prolong Pharmaceuticals.\\n \\n \\n \\n \\n URL:\\n https://www.clinicaltrials.gov\\n ; Unique identifier: NCT04677777.\\n \\n\",\"PeriodicalId\":21977,\"journal\":{\"name\":\"Stroke: Vascular and Interventional Neurology\",\"volume\":\"27 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Stroke: Vascular and Interventional Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1161/svin.123.001246\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stroke: Vascular and Interventional Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1161/svin.123.001246","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

PP-007 是一种聚乙二醇(PEG)酰化的牛羧基血红蛋白气体传递分子,具有多向细胞保护作用、血管扩张作用、血浆扩容作用和优化氧输送作用。啮齿类动物大脑中动脉闭塞模型表明,PP-007 可增加侧支循环血流量并减少最终梗死体积,从而支持其在急性缺血性中风中作为神经保护剂的潜在作用。我们旨在评估 PP-007 作为机械取栓术(MT)辅助治疗大血管闭塞继发性中风患者的安全性和可行性。 HEMERA-1(用于急性中风血管再通的羧基血红蛋白氧输送)是一项多中心、前瞻性、随机对照的一期临床试验。前循环大血管闭塞患者在症状出现后24小时内按3:1的比例被分配接受PP-007(320毫克/千克:30分钟栓塞后输注2小时)加MT或单独接受MT治疗。由独立的数据监控安全委员会和成像核心实验室进行全面的安全性评估。 从2021年10月1日至2022年6月30日,共招募了17名患者。年龄、美国国立卫生研究院卒中量表基线评分和阿尔伯塔卒中计划早期CT评分分别为74.8±12.7岁、17.3±4.2岁和7.9±1.8岁。12名患者随机接受了PP-007加MT治疗,1名患者接受了随机治疗但未接受治疗,4名患者随机接受了单用MT治疗。所有患者的闭塞血管都实现了再通畅。所有 PP-007 患者在用药期间都出现了短暂的收缩压升高(20-40 毫米汞柱),但未造成任何临床后果。没有其他安全问题。 在接受MT治疗的患者中辅助使用PP-007未发现重大安全问题。(该研究由 Prolong Pharmaceuticals 公司资助。 URL: https://www.clinicaltrials.gov ; Unique identifier:NCT04677777.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
HEMERA‐1 CarboxyHEMoglobin OxygEn Delivery for Evascularization in Acute Stroke: A Prospective, Randomized Phase 1 Clinical Trial
PP‐007 is a polyethylene glycol (PEG)ylated bovine carboxyhemoglobin gas transfer molecule with pleotropic cytoprotective effects, vasodilatation, plasma expansion, and optimization of oxygen delivery. Rodent middle cerebral artery occlusion models have demonstrated that PP‐007 increases blood flow in the collateral circulation and reduces final infarct volumes, supporting a potential role as neuroprotective agent in acute ischemic stroke. We aim to evaluate the safety and feasibility of PP‐007 as an adjunctive treatment to mechanical thrombectomy (MT) in patients with stroke secondary to large vessel occlusion. HEMERA‐1 (CarboxyHEMoglobin OxygEn delivery for Revascularization in Acute Stroke) was a multicenter, prospective, randomized, controlled phase 1 clinical trial. Anterior circulation large vessel occlusion patients were assigned in a 3:1 ratio to receive either PP‐007 (320 mg/kg: 30 min bolus followed by 2‐h infusion) plus MT or MT alone within 24 hours after symptom onset. Comprehensive safety evaluation was performed by independent Data Monitoring Safety Board and Imaging Core Lab. From October 1, 2021 to June 30, 2022, a total of 17 patients were recruited. Age, baseline National Institutes of Health Stroke Scale score, and Alberta Stroke Program Early CT Score were 74.8±12.7 years, 17.3±4.2, and 7.9±1.8, respectively. Twelve patients were randomized to PP‐007 plus MT, 1 was randomized but not treated, 4 patients were randomized to MT alone. Recanalization of the occluded vessel was achieved in all patients. A transient systolic blood pressure increase (20–40 mm Hg) during the bolus was observed in all PP‐007 patients without any clinical consequences. There were no other safety concerns. No significant safety concerns were identified for the adjunctive use of PP‐007 in patients undergoing MT. (The study was funded by Prolong Pharmaceuticals. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04677777.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Prognostication Following Aneurysmal Subarachnoid Hemorrhage: The Modified Hunt and Hess Grading Scale Intra‐arterial Selective Bevacizumab Administration in the Middle Meningeal Artery for Chronic Subdural Hematoma: An Early Experience in 12 Hemispheres Sex Disparities in Mortality After Endovascular Therapy in Large Core Infarcts Predicting Recanalization Failure With Conventional Devices During Endovascular Treatment Related to Vessel Occlusion Antiplatelet Therapy and Platelet Activity Testing for Neurointerventional Procedures
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1